Navigation Links
Isis Reports Financial Results and Highlights for 2012
Date:2/28/2013

CARLSBAD, Calif., Feb. 28, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2012 financial results and reviewed the highlights of the year.  Isis ended the year in a strong financial position significantly outperforming both its pro forma net operating loss (NOL) guidance and its cash guidance for the year.  For the year ended December 31, 2012, Isis had an NOL of $60.4 million compared to $61.3 million for 2011.  Isis added a substantial amount of cash to its balance sheet throughout 2012, ending the year with nearly $375 million.  On a GAAP basis, Isis reported a loss from operations of $26.1 million and $68.9 million for the three and twelve months ended December 31, 2012, respectively, compared to $18.6 million and $71.1 million for the same periods in 2011. 

"Last month the FDA approved KYNAMRO™.  KYNAMRO is the first systemic antisense drug to be sold commercially.  This is an important event for patients with homozygous familial hypercholesterolemia, for Isis, and for our antisense technology.  KYNAMRO's approval for chronic use in patients who have a severe and fatal disease highlights the potential of our technology to create drugs that could provide benefit for patients," said B. Lynne Parshall, chief operating officer of Isis.  "In addition to KYNAMRO, we have a number of promising new drugs that will report later-stage clinical data this year, setting us up for an exciting year of pipeline activity."

"2012 was a strong year for Isis.  We begin 2013 in a significantly improved financial position with nearly $375 million in cash.  Since the beginning of 2013, we have already received a $25 million milestone payment from Genzyme and a $7.5 million milestone payment from GSK.  With the commercial launch of KYNAMRO and a maturing pipeline of drugs, we have many
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
2. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
3. Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65
4. HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
5. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
6. Kewaunee Scientific Reports Improved Results for Third Quarter
7. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
8. Questcor Reports Fourth Quarter and Full Year 2012 Results
9. ResearchMoz: Global MRI Systems Market to 2018 - Technological Advancements, Increasing Number of Applications and Advent of MRI Compatible Pacemakers to Drive Future Growth - Market Research Reports
10. United Therapeutics Corporation Reports 2012 Fourth Quarter and Annual Financial Results
11. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... 2011 Reportlinker.com announces that ... is available in its catalogue: ... Drug Safety Strategies and Risk ... clinical success ...
... FRANCISCO, Calif., Oct. 26, 2011 Onyx Pharmaceuticals, ... results from a Bayer HealthCare Pharmaceuticals Phase 3 ... for the treatment of patients with metastatic colorectal ... standard therapies. The trial met its primary endpoint ...
Cached Medicine Technology:Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 2Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 3Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 4Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 5Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 6Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 7Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 8Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 2Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 3Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 4Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 5
(Date:12/26/2014)... December 26, 2014 Pentec Health, Inc. ... the state of Pennsylvania for 2014. The awards program, ... programs of its kind in the country. The program ... Pennsylvania Department of Community and Economic Development, the Pennsylvania ... and the Central Penn Business Journal. , ...
(Date:12/25/2014)... The click strand woven bamboo ... durability. Today, the business announces a click strand ... Jan. 30, 2015. , Click strand woven bamboo ... is a well-known brand in the bamboo industry. ... a reliable bamboo flooring supplier. , “We are ...
(Date:12/25/2014)... 2014 Recently, iFitDress.com, the popular online supplier ... announced its new selection of black one-shoulder cocktail dresses ... now; they are available at discounted prices, up to 70% ... will last for three weeks only. You know, we have ... are interested in our new items can visit our website ...
(Date:12/25/2014)... Hills, California (PRWEB) December 25, 2014 ... her home in Woodland Hills, California after an 8 ... passed away on Christmas Eve evening in her home ... with aggressive metastatic breast cancer. , ... for over forty years, she pioneered and championed many ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... , , , , ... of the 32 filed cases around the country have filed a joint ... to Chief Judge James G. Carr of the United States District Court ... July 24, 2009, before the Judicial Panel on Multidistrict Litigation in Washington, ...
... MONICA, Calif., July 24 The following advisory was issued by Consumer Watchdog: , , ... health insurance , , When : , ... , Hilton , Civil Justice Foundation Breakfast of Champions , ... San Francisco, CA 94102 , , What : , ...
... , , WASHINGTON, July 24 ... Department of Veterans Affairs (VA) medical centers, attained over one billion ... , , "Using this technology, ... database, allowing VA physicians immediate access to patient records regardless of ...
... The Hispanic got milk? Milk Mustache,Mobile Tour visited New York as ... to reintroduce Hispanics to this nutrient powerhouse and its,array of benefits. ... local residents not only to live well, but to drink well,with ... the events, Hispanic mothers were given the opportunity to enter the,Milk ...
... Medicine finds suggestive but limited evidence that exposure to Agent ... associated with an increased chance of developing ischemic heart disease ... the latest in a congressionally mandated series by the IOM ... effects of these herbicides and a type of dioxin -- ...
... , , OKLAHOMA CITY, July ... continues to see job opportunities for qualified professionals in the Oklahoma City, ... 6%, Adecco USA currently has demand for 100 pharmacy technicians in the ... , , Over the past year the ...
Cached Medicine News:Health News:Motion Filed to Consolidate Yasmin/YAZ Litigation in Toledo, Ohio 2Health News:CIGNA Whistleblower Calls for More Heath Insurance Accountability in Heath Care Reform 2Health News:VA Medical Imaging Reaches Record Level 2Health News:The Hispanic got milk? Campaign Visited New York July 18 - July 22 2Health News:Limited data suggest possible association between Agent Orange exposure 2Health News:Limited data suggest possible association between Agent Orange exposure 3Health News:Wanted: Oklahoma City Licensed Pharmacy Technicians 2
For use with catalog #0540....
Enzyme Immunoassay of D-Dimer by ELISA Method, 96 tests....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Latex Agglutination Slide Test for the Qualitative and Semi-Quantitative Determination of D-Dimer in plasma, 60 tests....
Medicine Products: